Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection

Paolo S. Silva; Ravinder J. Singh; Sophie J. Bakri; Ramil S. Lising; Darby E. Santiago; Harvey S. Uy

doi:10.1080/09273940802687838

Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection

Paolo S. Silva, Ravinder J. Singh, Sophie J. Bakri, Ramil S. Lising, Darby E. Santiago, Harvey S. Uy

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Purpose: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. Methods: TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. Results: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). Conclusion: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.

Original language	English (US)
Pages (from-to)	216-220
Number of pages	5
Journal	Ocular Immunology and Inflammation
Volume	17
Issue number	3
DOIs	https://doi.org/10.1080/09273940802687838
State	Published - Jun 2009

Keywords

Corticosteroids
Peribulbar injection
Transseptal injection
Triamcinolone acetonide
Vitreous concentration

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

Access to Document

10.1080/09273940802687838

Cite this

@article{26b203013d6040fe8c00e6ef0e40280d,

title = "Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection",

abstract = "Purpose: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. Methods: TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. Results: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). Conclusion: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.",

keywords = "Corticosteroids, Peribulbar injection, Transseptal injection, Triamcinolone acetonide, Vitreous concentration",

author = "Silva, {Paolo S.} and Singh, {Ravinder J.} and Bakri, {Sophie J.} and Lising, {Ramil S.} and Santiago, {Darby E.} and Uy, {Harvey S.}",

note = "Funding Information: Received 24 June 2008; Accepted 9 December 2008. Supported in part by a research grant from the Research Implementation and Development Office, College of Medicine, University of the Philippines, Manila. This paper was presented as a Poster at the Annual Meeting of the American Academy of Ophthalmology in Las Vegas, November 10– 14, 2006.",

year = "2009",

month = jun,

doi = "10.1080/09273940802687838",

language = "English (US)",

volume = "17",

pages = "216--220",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection

AU - Silva, Paolo S.

AU - Singh, Ravinder J.

AU - Bakri, Sophie J.

AU - Lising, Ramil S.

AU - Santiago, Darby E.

AU - Uy, Harvey S.

N1 - Funding Information: Received 24 June 2008; Accepted 9 December 2008. Supported in part by a research grant from the Research Implementation and Development Office, College of Medicine, University of the Philippines, Manila. This paper was presented as a Poster at the Annual Meeting of the American Academy of Ophthalmology in Las Vegas, November 10– 14, 2006.

PY - 2009/6

Y1 - 2009/6

N2 - Purpose: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. Methods: TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. Results: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). Conclusion: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.

AB - Purpose: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. Methods: TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. Results: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). Conclusion: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.

KW - Corticosteroids

KW - Peribulbar injection

KW - Transseptal injection

KW - Triamcinolone acetonide

KW - Vitreous concentration

UR - http://www.scopus.com/inward/record.url?scp=68849129368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849129368&partnerID=8YFLogxK

U2 - 10.1080/09273940802687838

DO - 10.1080/09273940802687838

M3 - Article

C2 - 19585367

AN - SCOPUS:68849129368

SN - 0927-3948

VL - 17

SP - 216

EP - 220

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 3

ER -

Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this